Humalog Mix25 (Insulin Lispro)

Humalog Mix25 is indicated for the management of blood glucose in adults with diabetes as part of a comprehensive treatment plan that may include diet, exercise, and other medications.

• Type 1 diabetes mellitus (insulin‑dependent)
• Type 2 diabetes mellitus when oral agents are insufficient
• Adjunct to basal insulin therapy for post‑prandial glucose control
• Use in patients requiring rapid onset insulin for mealtime coverage
• May be employed in insulin pump therapy when a mixed formulation is appropriate

• Insulin lispro in Humalog Mix25 binds to insulin receptors on muscle and adipose tissue, rapidly activating the receptor’s tyrosine kinase activity. This stimulates translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake, and suppresses hepatic gluconeogenesis, leading to lowered blood glucose levels. The lispro molecule’s altered amino‑acid sequence reduces self‑association, providing a faster onset of action compared with regular human insulin.

Adverse reactions to Humalog Mix25 can vary in frequency and severity.

Common

• Mild hypoglycemia (low blood sugar)
• Injection site redness or swelling
• Lipodystrophy at the injection site
• Transient nausea or abdominal discomfort
• Headache or dizziness

Serious

• Severe hypoglycemia requiring assistance
• Anaphylactic or severe allergic reaction
• Persistent edema or heart failure exacerbation

When using Humalog Mix25, several safety considerations should be observed.

• Monitor blood glucose regularly to avoid hypoglycemia.
• Adjust dose during periods of illness, stress, or changes in diet.
• Use caution in patients with renal or hepatic impairment.
• Do not use if you have a known hypersensitivity to insulin lispro or any excipients.
• Pregnant or breastfeeding individuals should consult a healthcare professional before use.
• Store the product according to label instructions and discard after the indicated period once opened.

Humalog Mix25 may interact with other substances that affect blood glucose or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without proper dose adjustment.
• Alcohol excess, which can potentiate hypoglycemia.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which can raise blood glucose levels.
• Thyroid hormones, which may alter insulin requirements.